BEN heads into the tail end of earnings week with its most concentrated burst of analyst upgrades in months, a stock that has ripped 7% in a week, and options positioning that is nearly as bullish as it has been all year.
The catalyst is clear. Franklin Resources reported fiscal Q2 results on April 28, and the stock jumped nearly 7% on the day. That reaction follows a more muted 2.8% gain after the previous print in February — the market clearly liked this one more. Multiple brokers responded within hours of the release, lifting price targets across the board. JP Morgan's Kenneth Worthington raised his target to $31 from $28 while keeping a Neutral rating. Goldman Sachs lifted to $34 from $30.50, maintaining Buy. TD Cowen bumped to $37 from $33, also keeping Buy. The most notable move came from Barclays, where Benjamin Budish upgraded from Underweight to Equal-Weight and raised his target to $31 from $26 — a meaningful shift from a house that had been firmly negative. Even Evercore ISI, the lone Underperform on the panel, nudged its target to $28 from $27. The consensus remains cautious — five Holds, one Underperform, and only a handful of Buy ratings — but the direction of travel on targets is unambiguously higher.
Options traders turned bullish well ahead of the print. The put/call ratio dropped to 0.36 on April 29, nearly 1.8 standard deviations below its 20-day average of 0.48 and close to the lowest reading of the past year (the 52-week floor is 0.30). That means call buying has dominated options flow in a way that is unusual for this stock. The shift has been visible over several sessions: the PCR was running above 0.55 through most of March and early April before dropping sharply in the final two weeks of the month. Whoever was positioning in the options market into earnings got the direction right.
Short positioning tells a quieter story. Short interest fell roughly 1.3% over the week to 4.6% of the free float — not a screaming crowded trade, but not trivially low either. Days to cover are running at 5.5 on the official FINRA data. The borrow market is loose: the cost to borrow is a negligible 0.56%, and availability is wide. There is no squeeze dynamic here. Short sellers have been gradually trimming since mid-April, when short interest was closer to 4.9%, and that trend continued through the earnings reaction. The ORTEX short score of 49.4 places BEN right in the middle of the range — neither extreme.
Valuation has re-rated materially over the month. The price-to-book ratio has risen 0.27 turns over the past 30 days to 1.30x, and the PE multiple has expanded by nearly 1.8 turns to 10.5x. Neither reads as stretched for an asset manager — EV/EBITDA is at 7.3x — but the pace of re-rating is worth noting given that the stock was trading closer to $22 in December. The 30-day price return is effectively identical to the closing price itself, a quirk of the data, but the directional story is consistent: the stock has recovered sharply from the lows. Factor scores are decent rather than exceptional — EPS momentum is in the 61st percentile on a 30-day basis and 68th on 90 days, while the dividend score ranks in the 98th percentile, reflecting BEN's status as a reliable income name.
Among correlated peers, the week's performance stands out. VCTR gained about 2.4% on the week, and MC added 1.4%, but EVR fell 3.7%, PIPR dropped 3.7%, and CG declined more than 8%. BEN's 7% gain is a clear outlier in the peer group, driven by its own fundamental catalyst rather than sector tailwinds.
The watch item from here is whether the Barclays upgrade proves a pivot point for broader sentiment. The consensus is still centred on Hold, and Evercore's Underperform target of $28 sits below the current $29.45 price — meaning one analyst already has a price target implying downside. How the street updates models after seeing the full earnings detail, and whether more upgrades follow Barclays' lead, will shape where BEN trades heading into summer.
See the live data behind this article on ORTEX.
Open BEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
